Journal of the American Academy of Dermatology
Volume 61, Issue 3 , Pages 405-410 , September 2009

The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis

  • Maryanne Makredes, MD

      Affiliations

    • Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
    • ,
  • Don Robinson Jr., MSPH

      Affiliations

    • Johnson & Johnson Pharmaceutical Services, Malvern, Pennsylvania
    • ,
  • Mohan Bala, PhD

      Affiliations

    • GlaxoSmithKline, Collegeville, Pennsylvania
    • ,
  • Alexa B. Kimball, MD, MPH

      Affiliations

    • Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: Alexa B. Kimball, MD, MPH, Clinical Unit for Research Trials in Skin, Department of Dermatology, Massachusetts General Hospital, 50 Staniford St, #240, Boston, MA 02115.

,Accepted 8 February 2009.

References 

  1. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2002;345:340–350
  2. Boren E, Gershwin ME. Inflamm-aging: autoimmunity and the immune-risk phenotype. Autoimm Rev. 2004;3:401–406
  3. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–1922
  4. Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care. 2002;8:S664–S681
  5. Robinson D, Hackett M, Wong J, Kimball AB, Cohen R, Bala M. The IMID Study Group. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin. 2006;22:989–1000
  6. Kimball AB, Robinson D, Wu Y, Guzzo C, Yeilding N, Paramore C, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology. 2008;217:27–37
  7. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol. 2008;7:373–377
  8. Tam LS, Tomlinson B, Chu TT-W, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls–the role of inflammation. Rheumatology (Oxford). 2008;47:718–723
  9. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–835
  10. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537–1541
  11. Ferrandiz C, Bordas X, Garcia-Patos V, Puig S, Pujol R, Smandia A. Prevalence of psoriasis in Spain. J Eur Acad Dermatol Venereol. 2001;15(36):20–23
  12. Hellgren L. Association between rheumatoid arthritis and psoriasis in total populations. Acta Rheumatol Scand. 1969;15:316–326
  13. Elkayam O, Ophir J, Yaron M, Caspi D. Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol. 2000;19:301–305
  14. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl):ii18–23
  15. Ciocon DH, Kimball AB. Psoriasis and psoriatic arthritis: separate or one in the same?. Br J Dermatol. 2007;157:850–860
  16. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum. 2004;50:34–35
  17. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med. 2007;175:875–880
  18. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol. 2007;56:629–634
  19. Ramos-Casals M, Brito-Zeron P, Font J. The overlap of Sjogren's syndrome with other systemic autoimmune diseases. Sem Arthritis Rheum. 2007;36:246–255
  20. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–1640
  21. Li J, Chen X, Liu Z, Yue Q, Liu H. Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technolog Med Sci. 2007;27:330–332
  22. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580–592
  23. Cohen R, Robinson D, Paramore C, Fraeman K, Renahan K, Bala B. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis. 2008;14:738-43
  24. Icen M, Crowson CS, McEnvoy MT, Gabriel SE, Maradit Kremers H. Potential misclassification of patients with psoriasis in electronic databases. J Am Acad Dermatol. 2008;59:981–985
  25. Peterson E, Van Vorst K, Wickstrom S, Levin R, Kerr EA, Schenker E, et al. The effect of chronic disease on risk of disenrollment from five United Healthcare-affiliated health plans. In:  McGlynn EA editors. Exploring issues in managed care: six illustrated case studies. Santa Monica, CA: RAND; 2001;p 11, 16-20, Appendix 1A

 Data acquisition was supported by Centocor.

 Disclosure: Mr Robinson is an employee and stockholder of Johnson & Johnson. Dr Bala is a stockholder of Johnson & Johnson and an employee of Glaxo Smith Kline. Dr Kimball has been an investigator, speaker, and consultant for Abbott, Centocor, and Amgen. Dr Makredes has no conflicts of interest to declare.

 Presented in part in poster format at the Society of Investigative Dermatology Annual Meeting in Kyoto, Japan, May 14-18, 2008.

PII: S0190-9622(09)00235-7

doi: 10.1016/j.jaad.2009.02.015

Journal of the American Academy of Dermatology
Volume 61, Issue 3 , Pages 405-410 , September 2009

Article Tools